Showing results (41-50 of 69) with videos related to
Sort By:
Pageof 7
Circulation|July 13, 2005
Cardiospecific overexpression of the prostaglandin EP3 receptor attenuates ischemia-induced myocardial injuryMelanie Martin, Jutta Meyer-Kirchrath, Gernot Kaber, et al.Vascular Pharmacology|June 16, 2016
Dipyrone comedication in aspirin treated stroke patients impairs outcomeLisa Dannenberg, Vladimir Erschoff, Florian Bönner, et al.Pharmacology & Therapeutics|October 16, 2018
Non-vitamin K oral anticoagulants (NOAC) and the risk of myocardial infarction: Differences between factor IIa and factor Xa inhibition?Amin Polzin, Lisa Dannenberg, Georg Wolff, et al.Pharmacology|October 26, 2018
Malondialdehyde Assay in the Evaluation of Aspirin Antiplatelet EffectsAmin Polzin, Lisa Dannenberg, Theresa Schneider, et al.Journal of Thrombosis and Thrombolysis|November 7, 2019
Platelet reactivity in patients with chronic kidney disease and hemodialysisPhilipp Mourikis, Carolin Helten, Lisa Dannenberg, et al.Pharmacology|June 15, 2017
Thromboxane Formation Assay to Identify High On-Treatment Platelet Reactivity to AspirinAnnemarie Mohring, Kerstin Piayda, Lisa Dannenberg, et al.Cardiovascular Research|November 21, 2008
Overexpression of prostaglandin EP3 receptors activates calcineurin and promotes hypertrophy in the murine heartJutta Meyer-Kirchrath, Melanie Martin, Christina Schooss, et al.Vascular Pharmacology|December 22, 2019
Aspirin antiplatelet effects are associated with body weightPhilipp Mourikis, Saif Zako, Lisa Dannenberg, et al.Thrombosis and Haemostasis|January 20, 2017
Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE)Uwe Zeymer, Thomas Hohlfeld, Jürgen Vom Dahl, et al.Pharmacology & Therapeutics|June 4, 2020
Lipid lowering therapy in cardiovascular disease: From myth to molecular realityPhilipp Mourikis, Saif Zako, Lisa Dannenberg, et al.Pageof 7